menu
    • menu
    [{"orgOrder":0,"company":"Tenpoint Therapeutics","sponsor":"Visus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Carbachol","moa":"||M1 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tenpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tenpoint Therapeutics \/ Visus Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Tenpoint Therapeutics \/ Visus Therapeutics"},{"orgOrder":0,"company":"Tenpoint Therapeutics","sponsor":"British Patient Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Tenpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal","sponsorNew":"Tenpoint Therapeutics \/ British Patient Capital","highestDevelopmentStatusID":"3","companyTruncated":"Tenpoint Therapeutics \/ British Patient Capital"},{"orgOrder":0,"company":"Tenpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Carbachol","moa":"||M1 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tenpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tenpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenpoint Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Tenpoint Therapeutics

    Menu

    Tenpoint Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tenpoint Therapeutics

                            United Kingdom arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            Tenpoint Therapeutics

                            United Kingdom arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Carbachol,Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tenpoint Therapeutics Announces Phase 3 BRIMOCHOL™ PF Data for Presbyopia

                            Details : Brimochol PF is a fixed-dose combination of carbachol and brimonidine tartrate that improves near vision in presbyopia by reducing pupil size to create a "pinhole effect," enhancing depth of focus.

                            Product Name : Brimochol PF

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 09, 2025

                            Lead Product(s) : Carbachol,Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tenpoint Therapeutics

                            United Kingdom arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            Tenpoint Therapeutics

                            United Kingdom arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Carbachol,Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Visus Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            2 Eye Disease Biotechs Merge, Set Sights on FDA Approval

                            Details : The merger brings together a late-stage, potentially best-in-class, presbyopia-correcting eye drop, Brimochol PF, on track for NDA filing, with a promising pipeline of innovative therapeutics.

                            Product Name : Brimochol PF

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 12, 2024

                            Lead Product(s) : Carbachol,Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Visus Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tenpoint Therapeutics

                            United Kingdom arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            Tenpoint Therapeutics

                            United Kingdom arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Study Phase : Discovery Platform

                            Sponsor : British Patient Capital

                            Deal Size : $70.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Tenpoint Therapeutics Launches with $70 Million Series A Financing to Reverse Vision Loss Through Engineered C...

                            Details : Tenpoint will use the net proceeds to develop its regenerative medicine platform to replace multiple cell types lost to inherited and age-related conditions.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 07, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Discovery Platform

                            Sponsor : British Patient Capital

                            Deal Size : $70.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth